Abstract：Objective To analyze the survival time and its influencing factors in HIV/AIDS patients in Yining City, Xinjiang from 2006 to 2015. Methods A retrospective cohort study was conducted to analyze the information of 6,437 HIV/AIDS patients reported by Chinese HIV/AIDS Comprehensive Prevention and Treatment Information Management System in Yining City, Xinjiang from 2006 to 2015. Life table method was applied to calculating the survival rate of the patients. Kaplan-Merier and Cox proportion hazard regression model were used to identify the factors affecting their survival time. Results Among the 6,437 patients, 1,016(15.8%)died of AIDS-related diseases and 3,687(57.3%)received antiretroviral therapy. The average survival time was 100.0(98.9-101.1)months, and the 1-, 3-, 5-, 7- and 9-year survival rates were 93.0%,86.0%, 82.0%, 80.0% and 78.0% respectively. Univariate analysis showed that gender, age, nationality, educational background, transmission route, AIDS phase, CD4+T cell count in the last testing and receiving antiretroviral therapy or not were the factors influencing their survival time. Multivariate Cox regression showed that confirming HIV/AIDS infection at the age of 45 years or below (as compared with 18-29 years old: HR=0.339, 95%CI:0.172-0.665; as compared with 30- years old: HR=0.800, 95%CI:0.666-0.961), confirming HIV/AIDS infection in HIV infection stage (HR=0.334, 95%CI:0.270-0.412) and CD4+T cell count in the last testing ≥ 350/μl (HR=0.281, 95%CI:0.222-0.356) could reduce the risk of AIDS-related death. The patients that did not receive antiretroviral therapy had a higher risk of AIDS-related death (HR=0.243, 95%CI: 0.204-0.290) than those did. Conclusions The survival time of HIV-infected individuals and AIDS patients is influenced by their age of diagnosis with AIDS, HIV/AIDS phase, CD4+T cell count and whether or not received antiretroviral therapy. Earlier initiation of antiretroviral therapy in AIDS patients can extend their survival time.
[1] 倪明健,陈晶,张艺,等. 新疆艾滋病流行状况分析[R]. 疾病预防控制通报,2012,27(1):1-3. [2] 张广,龚煜汉,王启兴,等. 四川省凉山州2004-2012年接受抗病毒治疗的艾滋病患者生存状况分析[J]. 中华流行病学,2014,35(12):1329-1332. [3] 孔维宾,韩丹,孙洁,等. 2003-2013年开封市艾滋病抗病毒治疗患者生存分析[J]. 河南大学学报,2015,34(2):128-132. [4] 陈洪森,温金平,黄晓明,等. 1999-2011年岑溪市艾滋病感染者及病人生存分析[J]. 实用预防医学, 2013,20(6):681-683. [5] 洪波,谢年华,曹倍辈,等.武汉市艾滋病患者生存时间及影响因素分析[J].中国公共卫生,2013,29(8):1097-1101. [6] Harrison KM,Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States[J]. J Acquir Immune Defic Syndr,2010,53(1):124-130. [7] Hall HI, Mcdavid K, Ling Q, et al. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001[J]. Ann Epidemiol, 2006,16(11):824-833. [8] 赖文红,喻航,罗映娟,等.四川省艾滋病抗病毒治疗患者生存时间分析[J].中国公共卫生,2011,27(12):1521-1522. [9] May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1:UK Collaborative HIV Cohort(UK CHIC) Study[J]. BMJ,2011,343:d6016. [10] 张福杰.国家免费艾滋病抗病毒药物治疗手册[M].第3版.北京:人民卫生出版社,2013:21-22. [11] 赵玉遂,荆波,刘少楠,等.HAART对AIDS患者中短期Meta分析[J]. 中国艾滋病性病,2012,18(2):79-81,106.
2017, Vol. 24 
